2025-521875-30-00招募中2 期
An open-label, phase 2 study, evaluating the efficacy of treatment with Gilteritinib in measurable residual disease eradication in patients with FLT3-ITD mutated acute myeloid leukemia
Hellenic Society Of Hematology4 个研究点 分布在 1 个国家目标入组 58 人开始时间: 2025年11月20日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 58
- 试验地点
- 4
- 主要终点
- The rate of FLT3-ITD MRD negativity after 2 cycles of treatment with Gilteritinib.
研究概览
简要总结
To evaluate the efficacy of Gilteritinib treatment in eradication of measurable residual disease (MRD) by PCR-NGS for FLT3-ITD.
研究设计
- 分配方式
- Non-randomized
- 主要目的
- Treatment period
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Patients must provide signed and dated informed consent for the study that has been approved by an Independent Ethics Committee (IEC) and the relevant Institution Review Board (IRB) of each participating centre, before performing any screening or study procedure.
- •Female patients of reproductive potential using hormonal contraceptives should add a barrier method of contraception.
- •Female subjects of child-bearing potential are eligible if they commit to contraception and if they are not pregnant, breastfeeding, nor considering becoming pregnant during the study or for at least 6 months after the last dose of Gilteritinib.
- •If male, and subject is sexually active with female partner(s) of childbearing potential, he must agree, to use effective contraception during treatment and for at least 4 months after the last dose of Gilteritinib.
- •Subjects must be willing and able to return to the clinical site for adequate follow-up and to comply with the protocol as required.
- •Patients with positive MRD (by PCR-NGS for FLT3-ITD) after 2 cycles of intensive chemotherapy in combination with an FLT3- inhibitor will be eligible for enrolment.
- •Adult male or female patients.. Aged 18 – 75 years old on the day of signing informed consent.
- •Subjects must have a new diagnosis of primary/de novoFLT3-ITD mutated AML according to the WHO criteria (2017).
- •Body weight >40kg.
- •Subjects must be willing and able to comply with the relevant procedures, according to the protocol.
- •Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of < 2 (See Appendix 1: ECOG Performance Status).
- •Subjects must have an estimated life expectancy of >3 months.
- •Female patients of childbearing potential: negative serum pregnancy test at the screening visit and negative urine pregnancy test within seven days prior to starting treatment with Gilteritib.
- •Female patients of reproductive potential must agree to use an effective method of contraception during treatment with Gilteritinib and for at least 6 months after stopping Gilteritinib.
排除标准
- •Subjects with secondary AML, including treatment-related [e.g., due to prior anthracycline use], as well as subjects with progression of antecedent hematological disorder [e.g., MDS, MPN or MDS/MPN ‘overlap’ syndrome].
- •History of clinically significant medical conditions or any other reason that the investigator determines would interfere with the subject's participation in this study or would make the subject an unsuitable candidate to receive study drug.
- •Subjects with acute promyelocytic leukemia.
- •Subjects with a serious concurrent illness that in the opinion of the Investigator would pose an undue risk to the subject participating in the clinical study (such as active/uncontrolled infection at the time of screening).
- •Subjects with a diagnosis of human immunodeficiency virus (HIV), active hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection. Subjects with HBV inactive carrier status and/or HCV with low viral titres on antivirals (non-exclusionary medications) are eligible. Low viral hepatitis titre is defined per institutional guidelines.
- •Known hypersensitivity to the active substance or to any of the excipients of Gilteritinib.
- •Has a known psychiatric or substance abuse disorder that would interfere with the participant’s ability to cooperate with the requirements of the study.
- •Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of Gilteritinib.
- •Patients not willing to comply with effective contraception.
- •Malabsorption syndrome or other condition that precludes oral route of administration.
结局指标
主要结局
The rate of FLT3-ITD MRD negativity after 2 cycles of treatment with Gilteritinib.
The rate of FLT3-ITD MRD negativity after 2 cycles of treatment with Gilteritinib.
次要结局
- Frequency and type of resistance mutations detected at relapse, with particular emphasis on the, RAS/MAPK pathway ( such as NRAS, KRAS, PTPN11, CBL, NF1).
- Time to development of resistance (e.g., median duration of treatment before resistance is observed).
- Phenotypic changes (via flow cytometry) associated with resistance. More specifically, phenotypes such as the CD34+CD38-CD123+ or the CD47, TIM-3, CD96 expression and the appearence/re-appearence of antigenic characterists will be evaluated.
- Baseline biomarker profiles (gene expression, mutation profile, proteomics) correlated with treatment response. More specifically, the presence of co-mutations in DNMT3A, NPM1, TET2, ASXL1, TP53 and the expression of antiapoptotic genes (such as the BCL2 and the MCL1) will be evaluated.
- Correlation between immune microenvironment features and response to treatment. More specifically, the expression of immunoregulatory molecules, such as the PD-L1, LAG-3, TIM-3 and the percentage of CD8+, T-regulatory and NK cells will be evaluated.
- Predictive value of specific genomic or transcriptomic signatures for MRD negativity.
研究者
Giorgos Vasilopoulos
Scientific
Hellenic Society Of Hematology
研究点 (4)
Loading locations...
相似试验
招募中
2 期
With Ponatinib on the track for treatment-free-remission in chronic myeloid leukemia2024-518971-76-00Heidelberg University17
招募中
2 期
An Open Label Study of JNJ-68284528, Directed Against BCMA in Subjects with Multiple MyelomaMultiple Myeloma2023-506587-13-00Janssen - Cilag International56
招募中
2 期
CHIP-AML22/Quizartinib sub-study: study of the safety and efficacy of quizartinib in children and adolescents with FLT3-ITD positive AML with normal NPM1.2023-505000-27-01Prinses Maxima Centrum voor Kinderoncologie B.V.60
招募中
3 期
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.2025-522860-34-00BeOne Medicines AG196
招募中
3 期
A Phase 3 Study Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib in Participants with Nonsegmental Vitiligo2022-501668-16-00Pfizer Inc.81